◆ NeutralLLYNVO

Eli Lilly's Next Big Growth Opportunity Could Be Hiding in Plain Sight

The Motley Fool·
Eli Lilly's Next Big Growth Opportunity Could Be Hiding in Plain Sight

Eli Lilly's weight-loss drug Zepbound showed strong clinical trial results in adolescents aged 12-17, with participants losing an average of 40 pounds and experiencing improved cardiovascular health markers. This could open a significant new market of over 5 million U.S. patients, potentially generating $6.5 billion in additional annual revenue. The company is also testing Zepbound in younger children aged 6-11, further expanding its addressable market despite competition from Novo Nordisk's Wegovy.

Read Full Article at The Motley Fool →
← Back to Financial Intelligence